In terms of market performance, Pacific Biosciences of California Inc had a fairly uneven. The highest value for the stock in the past year was $10.65 on 12/27/23, and the lowest value was recorded at $1.16 on 07/02/24.
52-week price history of PACB Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Pacific Biosciences of California Inc’s current trading price is -81.78% away from its 52-week high, while its distance from the 52-week low is 67.24%. The stock’s price range during the 52-week period has remained between $1.16 and $10.65. In the Healthcare sector, the company’s shares saw a trading volume of around 1.66 million for the day, which was evidently lower than the average daily volume of 9.47 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Pacific Biosciences of California Inc (PACB) has experienced a quarterly rise of 22.01% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 531.30M and boasts a workforce of 796 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.8182, with a change in price of +0.2650. Similarly, Pacific Biosciences of California Inc recorded 9,078,699 in trading volume during the last 100 days, posting a change of +15.87%.
Examining PACB’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for PACB stands at 2.03. Similarly, the long-term debt-to-equity ratio is also 2.01.
PACB Stock Stochastic Average
Pacific Biosciences of California Inc’s raw stochastic average for the past 50 days is presently 36.18%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 27.08%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 29.81% and 30.43%, respectively.
PACB Stock Price Performance Analysis
The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Until today this year the stock’s price performance recorded a decrease of -80.22%. However, over the last six months, the performance has been weaker by 43.17%. The price of PACB increased 7.78% over the last 30 days. And in the last five days, it has fallen by -1.52%.
